Recently, the therapies that aimed at VEGF-A as the target for the management of CNV associated with AMD have demonstrated encouraging signs of biologic activity with confirmed efficacy and safety such as the intravitreal injection of Pegaptanib [11] and Ranibizumab [12]. Here, VEGFA is linked to age-related macular degeneration.